Nls pharmaceutics releases the results from its annual general meeting

Zurich, switzerland / accesswire / june 30, 2023 / nls pharmaceutics ltd. (nasdaq:nlsp, nlspw) ("nls" or the "company"), a swiss clinical-stage biopharmaceutical company focused on the discovery and development of innovative therapies for patients with rare and complex central nervous system disorders, today announced that the nls shareholders approved all of the board of directors' proposals for the 2023 annual general meeting (agm) that took place in zÜrich, switzerland today.
NLSP Ratings Summary
NLSP Quant Ranking